AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25591636
Drug: XR‐NTX (380
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XR‐NTX (380 mg)
Trial: 18680075
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin (0.1 mg bolus, then 35 microg/kg/min for 6 hours, maximum dose 9 mg)
Trial: 15647969
Drug: 200 IU
RxNorm normalized name: Vitamin E 200 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 IU intranasal salmon calcitonin (Miacalcic nasal 200) daily, 1 month on-1 month off, 0.25 mug 1alpha(OH)D3, and 500 mg elemental calcium continuously
Trial: 15647969
Drug: 0.25 mug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mug 1alpha(OH)D3 and 500 mg elemental calcium
Trial: 12034414
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II receptor antagonists
Trial: 12034414
Drug: Losartan (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (reference drug)
Trial: 8017601
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine 300 micrograms
Trial: 1093426
Drug: Oral diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diazepam 10 mg
Trial: 9752388
Drug: Therapeutic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic mixture containing 10 mg of methylphenidate, 2.5 mg of methandrostenolone, and a mixture of B vitamins
Trial: 15475141
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) 0.05 mg/kg/day
Trial: 11501649
Drug: Nickel sulfate
RxNorm normalized name: Nickel Sulfate
DrugBank: Nickel sulfate (DB14180)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nickel sulfate patch test
Trial: 11501649
Drug: Potassium dichromate
RxNorm normalized name: Potassium dichromate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium dichromate patch test
Trial: 29947487
Drug: Intraperitoneal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal bupivacaine (40 ml of 0.25% solution)
Trial: 20450425
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration analgesia (LIA) with 400 mg ropivacaine, 30 mg ketorolac, and 0.5 mg epinephrine during operation and 200 mg ropivacaine, 30 mg ketorolac, and 0.1 mg epinephrine 21 h postoperatively
Trial: 20450425
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with no injections during operation and saline injection 21 h postoperatively
Trial: 18481390
Drug: Oregovomab immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oregovomab immunotherapy
Trial: 16527015
Drug: Tisseel (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tisseel (2 cc)
Trial: 12660408
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (CrH2O) supplementation (0.5 g x kg(‐1) FFM, one fourth dosage 4 times daily for 5 days)
Trial: 9014620
Drug: Neostigmine (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (doses > 20 micrograms kg-1)
Trial: 3926591
Drug: Cimetidine 600
RxNorm normalized name: cimetidine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 600 mg b.i.d.
Trial: 31032782
Drug: Memory rehabilitation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memory rehabilitation (10 weekly sessions of a manualised memory rehabilitation programme)
Trial: 29418016
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment with Sex Steroid Replacement Therapy (SSRT)
Trial: 26817525
Drug: Oral tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tramadol 50 mg
Trial: 22329446
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (physical therapy, topical dimethyl sulfoxide, analgesics, transcutaneous stimulation, sympathetic blockade)
Trial: 15744348
Drug: Intravenous 6-mercaptopurine
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous 6-mercaptopurine (1 g/m(2))
Trial: 15744348
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous 6-mercaptopurine (Control Group, Arm A)
Trial: 12173072
Drug: Prednisolone 20
RxNorm normalized name: prednisolone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 20 mg once a day for two days prior to HA and during initial three days at HA
Trial: 91437
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose cis-platinum (1-hour infusion with mannitol diuresis)
Trial: 91437
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cis-platinum (8-hour infusion without diuresis)
Trial: 91437
Drug: Three-drug program
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug program (vinblastine, actinomycin D, and cis-platinum)
Trial: 91437
Drug: Cyclic crossover
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic crossover regimen (three regimens each containing three drugs)
Trial: 30854443
Drug: DCE-MRI before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCE-MRI before radiation therapy (pre-RT)
Trial: 30854443
Drug: DCE-MRI after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCE-MRI after 2 weeks of radiation therapy (2wkRT)
Trial: 27657674
Drug: Ramucirumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab (8 mg/kg) plus best supportive care
Trial: 25461393
Drug: alendronate 70mg
RxNorm normalized name: ALENDRONATE 70MG TAB
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: alendronate 70mg weekly
Trial: 10772372
Drug: Personalized follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized follow-up (weekly telephone contact for 12 weeks)
Trial: 3537249
Drug: Methionyl human
RxNorm normalized name: Recombinant methionyl human bdnf
DrugBank: Recombinant methionyl brain-derived neurotrophic factor (DB16970)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionyl human growth hormone (0.125 mg/kg three times per week)
Trial: 3537249
Drug: Oxandrolone (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone (0.125 mg/kg/day)
Trial: 3537249
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (hGH plus oxandrolone)
Trial: 28222552
Drug: Cognitive Orientation
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Orientation to daily Occupational Performance (CO‐OP) approach
Trial: 21601839
Drug: Judgments based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Judgments based on the agent's innocent intent regarding accidental harms.
Trial: 21601839
Drug: Judgments based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Judgments based on the agent's guilty intent regarding failed attempts to harm.
Trial: 17003082
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg every other day
Trial: 8196788
Drug: Preoperative instruction
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative instruction and physical therapy
Trial: 8196788
Drug: No preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preoperative instruction and physical therapy
Trial: 3359548
Drug: Low-residue diet
RxNorm normalized name: hydroxypropyl betadex (0.6 hydroxypropyl residues per glucose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-residue diet with an additional intake of 1200 Kcal and 32 g protein daily (Group B)
Trial: 3359548
Drug: Uninterrupted colonic
RxNorm normalized name: colonial bent grass pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uninterrupted colonic preparation with dietary restrictions for 4-8 days (450 calories; 25 g proteins daily) (Group A)
Trial: 20925067
Drug: Pramipexole 0.5
RxNorm normalized name: pramipexole 0.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 0.5 mg bid
Trial: 20925067
Drug: Pramipexole 0.75
RxNorm normalized name: pramipexole 0.75 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 0.75 mg bid
Trial: 20925067
Drug: Pramipexole 0.5
RxNorm normalized name: pramipexole 0.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 0.5 mg tid
Trial: 16740918
Drug: Thrombolytic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic treatment (TT)
Trial: 15541014
Drug: Atipamezole (three-step
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atipamezole (three-step infusion aiming for serum concentrations of 10, 30, and 90 ng ml(‐1))
Trial: 15541014
Drug: Atipamezole (three-step
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atipamezole (three-step infusion)
Trial: 8491246
Drug: Nitecapone 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitecapone 100 mg t.d.s. for 7 days
Trial: 3555605
Drug: 0.25% idoxuridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% idoxuridine ointment applied twice daily for 2 weeks
Trial: 3555605
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment applied twice daily for 2 weeks
Trial: 30032937
Drug: Individually-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individually-based treatment (IBT)
Trial: 30032937
Drug: Behavioral couples
RxNorm normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral couples therapy plus individually-based treatment (BCT + IBT)
Trial: 27311248
Drug: Dulaglutide (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide (subcutaneous 0.75 or 1.5 mg once weekly)
Trial: 27311248
Drug: Metformin, sitagliptin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin, sitagliptin, exenatide, insulin glargine
Trial: 25333428
Drug: Dental care
RxNorm normalized name: Arm And Hammer Dental Care Mint Toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental care provided by a dental surgeon, 4‐5 times a week, including routine oral hygiene, teeth brushing, tongue scraping, removal of calculus, atraumatic restorative treatment of caries, and tooth extraction
Trial: 25333428
Drug: Routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oral hygiene only, including the use of chlorhexidine as a mouth rinse, performed by ICU nurse staff
Trial: 25333428
Drug: Routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oral hygiene only
Trial: 23373662
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of opportunistic infections prophylaxis
Trial: 6138084
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg oxazepam
Trial: 21321086
Drug: Motesanib 125
RxNorm normalized name: Motesanib
DrugBank: Motesanib (DB05575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motesanib 125 mg once daily (qd)
Trial: 21321086
Drug: Motesanib 75
RxNorm normalized name: Motesanib
DrugBank: Motesanib (DB05575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motesanib 75 mg twice daily (b.i.d.) 5 days on/2 days off
Trial: 21321086
Drug: Bevacizumab 15
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 15 mg/kg every 3 weeks (q3w)
Trial: 15933353
Drug: Co-prescription of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-prescription of heroin (inhalable or injectable) over 12 months
Trial: 15933353
Drug: Methadone alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone alone (maximum 150 mg a day)
Trial: 12131942
Drug: Intramuscular diclofenac,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular diclofenac, 75 mg associated with intravenous physiological saline, 10 ml
Trial: 2468183
Drug: Single-agent ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-agent ifosfamide
Trial: 2468183
Drug: BIP combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIP combination (ifosfamide, cisplatin, and bleomycin)
Trial: 871634
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg prazosin with 100 mmol sodium intake
Trial: 871634
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg prazosin with 100 mmol sodium intake
Trial: 871634
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg prazosin with 250 mmol sodium intake
Trial: 871634
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg prazosin with 250 mmol sodium intake
Trial: 11425770
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Aspirin and Warfarin)
Trial: 11425770
Drug: Control (Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Placebo + Warfarin)
Trial: 11425770
Drug: Control (Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Placebo + Aspirin)
Trial: 30021096
Drug: l-glutamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-glutamine (0.3 g/kg per dose, administered twice daily)
Trial: 26718379
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (940-nm gallium-aluminum-arsenic diode laser, 200 mW, 20 seconds at 3 points on buccal mucosa)
Trial: 26718379
Drug: Placebo laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo laser therapy (laser not turned on)
Trial: 22581038
Drug: Patient-specific carbohydrate
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-specific carbohydrate absorption factor
Trial: 22581038
Drug: BG-dependent variable
RxNorm normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BG-dependent variable insulin appearance rate
Trial: 17275636
Drug: Warfarin dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin dosing by nomogram
Trial: 17275636
Drug: Warfarin dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin dosing by house staff
Trial: 12851279
Drug: Tifacogin (0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tifacogin (0.025 mg/kg per hour for 96 hours, n = 880)
Trial: 10536644
Drug: Isoproterenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol infusion at incremental doses from 0.010 to 0.030 microgram kg‐1 min‐1
Trial: 30137664
Drug: Concizumab (0.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concizumab (0.25, 0.5, and 0.8 mg kg‐1, once every 4 days)
Trial: 30137664
Drug: Concizumab (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concizumab (highest dose cohort)
Trial: 23148736
Drug: Doripenem (7-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doripenem (7-day course, 1g as a four-hour infusion every eight hours)
Trial: 23148736
Drug: Imipenem-cilastatin (10-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem-cilastatin (10-day course, 1g as a one-hour infusion every eight hours)
Trial: 15857205
Drug: Spirulina (2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirulina (2,000 mg/day)
Trial: 15857205
Drug: Spirulina (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirulina (1,000 mg/day)
Trial: 10466547
Drug: DTPw-HBV combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPw-HBV combination vaccine containing 10 microg of HBsAg
Trial: 10466547
Drug: DTPw-HBV combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPw-HBV combination vaccine containing 5 microg of HBsAg
Trial: 10466547
Drug: Separate administration
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate administration of DTPw and HBV (10 microg of HBsAg)
Trial: 7838634
Drug: Glucose-ORS (G-ORS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-ORS (G-ORS)
Trial: 7838634
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (RF-ORS, G-ORS, RD-ORS)
Trial: 2244843
Drug: Ticlopidine (antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (antiplatelet agent)
Trial: 30836195
Drug: PEMF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEMF therapy (immediate post-surgery for 6 hours, then 3 hours for the next 6 days, and 1.5 hours for days 8-13)
Trial: 30836195
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (no extra treatment)
Trial: 23947742
Drug: PEMF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEMF therapy
Trial: 22521233
Drug: Antipsychotic medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medications (flexible dose of one of five antipsychotic medications)
Trial: 10102948
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg once daily for 2 weeks
Trial: 10102948
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg once daily for 4 weeks
Trial: 7766739
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily for 4 weeks
Trial: 7480102
Drug: Sugar-coated tablet
RxNorm normalized name: tiopronin
DrugBank: Tiopronin (DB06823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sugar-coated tablet formulation containing 50 mg standardized horse chestnut seed extract
Trial: 7480102
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation in capsule form containing 50 mg standardized horse chestnut seed extract
Trial: 7389382
Drug: 350 mg
RxNorm normalized name: hemin 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg pivampicillin 3-times daily
Trial: 7389382
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg doxycycline daily
Trial: 26002889
Drug: Oxygen (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen (8 L/min)
Trial: 22708612
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment (observation and immediate imitation of common daily hand and arm actions)
Trial: 22708612
Drug: Usual rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual rehabilitation without any trial-related treatment
Trial: 15366525
Drug: Chin cup
RxNorm normalized name: CHIN-UP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chin cup therapy
Trial: 3310569
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 to 160 mg/day)
Trial: 1704983
Drug: Felodipine plus
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine plus metoprolol 10 + 100 mg (FM)
Trial: 1704983
Drug: Felodipine 10
RxNorm normalized name: felodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 10 mg (F)
Trial: 1704983
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg (M)
Trial: 168121
Drug: Intravenous adrenocorticotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous adrenocorticotropic hormone (ACTH)
Trial: 31618446
Drug: Sertraline and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline and/or mirtazapine
Trial: 27600280
Drug: Paclitaxel-carboplatin-bevacizumab (PCB)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Paclitaxel-carboplatin-bevacizumab (PCB) with nitroglycerin patches
Trial: 27600280
Drug: Paclitaxel-carboplatin-bevacizumab (PCB)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Paclitaxel-carboplatin-bevacizumab (PCB) without nitroglycerin patches (control)
Trial: 24419513
Drug: Once-daily (QD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily (QD) administration of intra-venous (IV) BU